Radiation Oncology CME Courses

By the end of the session the participant will be able to:

• Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
• Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
• Identify present pharmacotherapeutic treatments for management of a patient receiving AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
• Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case

By the end of the session the participant will be able to:

• Apply existing guideline recommendations in the diagnosis of HCC
• Identify present and emerging pharmacotherapeutic treatments for management of unresectable HCC and apply them to patient cases using evidence-based medicine.
• Describe how to manage challenges that arise during treatment with present and emerging pharmacotherapeutic treatments for HCC, including adverse effect management, and apply that knowledge to a patient case
• Describe the challenges associated with treating patients with HCC, focusing specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents used to treat the disease, and apply that information in optimizing patient care in a patient case